vs

Side-by-side financial comparison of BRUNSWICK CORP (BC) and Edwards Lifesciences (EW). Click either name above to swap in a different company.

Edwards Lifesciences is the larger business by last-quarter revenue ($1.6B vs $1.4B, roughly 1.2× BRUNSWICK CORP). Edwards Lifesciences runs the higher net margin — 23.1% vs 1.5%, a 21.6% gap on every dollar of revenue. On growth, BRUNSWICK CORP posted the faster year-over-year revenue change (17.3% vs 16.7%). Over the past eight quarters, Edwards Lifesciences's revenue compounded faster (9.7% CAGR vs -2.3%).

Brunswick Corporation, formerly known as the Brunswick-Balke-Collender Company, is an American corporation that has been developing, manufacturing and marketing a wide variety of products since 1845. Brunswick has more than 13,000 employees in 24 countries. Brunswick owns a number of brands, including Mercury Marine. In 2024, Brunswick reported sales of US$5.2 billion. Brunswick's global headquarters is in the northern Chicago suburb of Mettawa, Illinois.

Edwards Lifesciences Corporation is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring. It developed the Sapien transcatheter aortic heart valve made of cow tissue within a balloon-expandable, cobalt-chromium frame, deployed via catheter.

BC vs EW — Head-to-Head

Bigger by revenue
EW
EW
1.2× larger
EW
$1.6B
$1.4B
BC
Growing faster (revenue YoY)
BC
BC
+0.6% gap
BC
17.3%
16.7%
EW
Higher net margin
EW
EW
21.6% more per $
EW
23.1%
1.5%
BC
Faster 2-yr revenue CAGR
EW
EW
Annualised
EW
9.7%
-2.3%
BC

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
BC
BC
EW
EW
Revenue
$1.4B
$1.6B
Net Profit
$21.0M
$380.7M
Gross Margin
24.9%
78.0%
Operating Margin
3.6%
1.8%
Net Margin
1.5%
23.1%
Revenue YoY
17.3%
16.7%
Net Profit YoY
6.8%
EPS (diluted)
$0.32
$0.66

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BC
BC
EW
EW
Q1 26
$1.4B
$1.6B
Q4 25
$1.3B
$1.6B
Q3 25
$1.4B
$1.6B
Q2 25
$1.4B
$1.5B
Q1 25
$1.2B
$1.4B
Q4 24
$1.2B
$1.4B
Q3 24
$1.3B
$1.4B
Q2 24
$1.4B
$1.4B
Net Profit
BC
BC
EW
EW
Q1 26
$21.0M
$380.7M
Q4 25
$18.7M
$91.2M
Q3 25
$-235.5M
$291.1M
Q2 25
$59.3M
$333.2M
Q1 25
$20.2M
$358.0M
Q4 24
$-82.5M
$385.6M
Q3 24
$44.6M
$3.1B
Q2 24
$100.0M
$366.3M
Gross Margin
BC
BC
EW
EW
Q1 26
24.9%
78.0%
Q4 25
23.1%
78.1%
Q3 25
25.8%
77.8%
Q2 25
25.5%
77.5%
Q1 25
24.9%
78.7%
Q4 24
21.9%
78.9%
Q3 24
26.2%
80.6%
Q2 24
27.1%
79.9%
Operating Margin
BC
BC
EW
EW
Q1 26
3.6%
1.8%
Q4 25
3.1%
9.6%
Q3 25
-17.8%
19.8%
Q2 25
7.1%
26.8%
Q1 25
4.6%
27.9%
Q4 24
-4.8%
22.6%
Q3 24
7.7%
25.9%
Q2 24
11.0%
26.8%
Net Margin
BC
BC
EW
EW
Q1 26
1.5%
23.1%
Q4 25
1.4%
5.8%
Q3 25
-17.3%
18.7%
Q2 25
4.1%
21.7%
Q1 25
1.7%
25.3%
Q4 24
-7.1%
27.8%
Q3 24
3.5%
226.7%
Q2 24
6.9%
26.7%
EPS (diluted)
BC
BC
EW
EW
Q1 26
$0.32
$0.66
Q4 25
$0.32
$0.16
Q3 25
$-3.59
$0.50
Q2 25
$0.89
$0.56
Q1 25
$0.30
$0.61
Q4 24
$-1.21
$0.65
Q3 24
$0.67
$5.13
Q2 24
$1.48
$0.61

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BC
BC
EW
EW
Cash + ST InvestmentsLiquidity on hand
$277.8M
Total DebtLower is stronger
$490.2M
Stockholders' EquityBook value
$1.6B
Total Assets
$5.5B
Debt / EquityLower = less leverage
0.31×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BC
BC
EW
EW
Q1 26
$277.8M
Q4 25
$256.8M
$4.2B
Q3 25
$297.7M
$3.8B
Q2 25
$315.7M
$4.1B
Q1 25
$286.7M
$3.9B
Q4 24
$269.0M
$4.0B
Q3 24
$284.1M
$4.4B
Q2 24
$494.5M
$2.0B
Total Debt
BC
BC
EW
EW
Q1 26
$490.2M
Q4 25
$2.1B
Q3 25
Q2 25
Q1 25
Q4 24
$2.4B
Q3 24
Q2 24
Stockholders' Equity
BC
BC
EW
EW
Q1 26
$1.6B
Q4 25
$1.6B
$10.3B
Q3 25
$1.6B
$10.2B
Q2 25
$1.9B
$10.5B
Q1 25
$1.9B
$10.1B
Q4 24
$1.9B
$10.0B
Q3 24
$2.0B
$9.5B
Q2 24
$2.0B
$7.4B
Total Assets
BC
BC
EW
EW
Q1 26
$5.5B
Q4 25
$5.3B
$13.7B
Q3 25
$5.4B
$13.3B
Q2 25
$5.8B
$13.5B
Q1 25
$5.9B
$13.0B
Q4 24
$5.7B
$13.1B
Q3 24
$6.0B
$13.0B
Q2 24
$6.4B
$10.1B
Debt / Equity
BC
BC
EW
EW
Q1 26
0.31×
Q4 25
1.30×
Q3 25
Q2 25
Q1 25
Q4 24
1.25×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BC
BC
EW
EW
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$-116.8M
FCF MarginFCF / Revenue
-8.5%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$344.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BC
BC
EW
EW
Q1 26
Q4 25
$132.9M
$450.9M
Q3 25
$140.4M
$573.7M
Q2 25
$316.2M
$290.2M
Q1 25
$-27.4M
$280.4M
Q4 24
$306.4M
$-127.5M
Q3 24
$67.4M
$351.8M
Q2 24
$211.0M
$371.5M
Free Cash Flow
BC
BC
EW
EW
Q1 26
$-116.8M
Q4 25
$83.6M
$353.5M
Q3 25
$106.5M
$516.2M
Q2 25
$271.3M
$240.9M
Q1 25
$-65.1M
$224.4M
Q4 24
$276.1M
$-177.3M
Q3 24
$31.4M
$299.9M
Q2 24
$163.9M
$286.1M
FCF Margin
BC
BC
EW
EW
Q1 26
-8.5%
Q4 25
6.3%
22.5%
Q3 25
7.8%
33.2%
Q2 25
18.7%
15.7%
Q1 25
-5.3%
15.9%
Q4 24
23.9%
-12.8%
Q3 24
2.5%
22.1%
Q2 24
11.4%
20.9%
Capex Intensity
BC
BC
EW
EW
Q1 26
4.2%
Q4 25
3.7%
6.2%
Q3 25
2.5%
3.7%
Q2 25
3.1%
3.2%
Q1 25
3.1%
4.0%
Q4 24
2.6%
3.6%
Q3 24
2.8%
3.8%
Q2 24
3.3%
6.2%
Cash Conversion
BC
BC
EW
EW
Q1 26
Q4 25
7.11×
4.94×
Q3 25
1.97×
Q2 25
5.33×
0.87×
Q1 25
-1.36×
0.78×
Q4 24
-0.33×
Q3 24
1.51×
0.11×
Q2 24
2.11×
1.01×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons